{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:15:10Z","timestamp":1783937710828,"version":"3.55.0"},"reference-count":17,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Tumori"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Germline pathogenic variants are increasingly recognized as critical determinants of pancreatic ductal adenocarcinoma (PDAC) susceptibility, prognosis, and response to targeted therapies such as PARP inhibitors. Recent guidelines recommend germline testing for all PDAC patients, regardless of family history, to identify hereditary cancer syndromes and guide treatment decisions. However, data from populations underrepresented in genomic studies, such as the Turkish population, remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We retrospectively analyzed 151 unselected PDAC patients who underwent germline testing using a next-generation sequencing (NGS) panel between January 2023 and April 2025. The panel covered established cancer susceptibility genes. Clinical parameters\u2014including age, sex, tumor location and stage, diabetes status, and cancer family history\u2014were reviewed. Variants were classified as pathogenic\/likely pathogenic (P\/LP), variants of uncertain significance (VUS), or benign.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among the 151 patients, 17 (11.3%) harbored P\/LP variants, most frequently in ATM (n=3), BRCA1 (n=2), BRCA2 (n=2), and CDKN2A (n=2). An additional 33 patients (21.9%) carried VUS, again most commonly affecting ATM. No benign variants were reported. Notably, 70.6% of P\/LP carriers had a first- or second-degree family history of cancer. Most tumors originated in the pancreatic head (72.8%), and 41.1% of patients had metastatic disease at diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our findings confirm the relevance of multigene panel testing in PDAC and reveal a germline mutation spectrum consistent with global data. These results support universal germline screening and emphasize the need for continued VUS interpretation, particularly in genomically understudied populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03008916251410475","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:21:12Z","timestamp":1769084472000},"page":"260-267","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and impact of germline mutations in pancreatic ductal adenocarcinoma"],"prefix":"10.1177","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5303-6590","authenticated-orcid":false,"given":"Emir Gokhan","family":"Kahraman","sequence":"first","affiliation":[{"name":"Department of Electrical and Electronics Engineering (Biomedical Technologies), Dokuz Eylul University, Izmir, T\u00fcrkiye"},{"name":"Department of Medical Oncology, Izmir City Hospital, Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halil","family":"Taskaynatan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Izmir City Hospital, Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha Re\u015fid","family":"\u00d6zdemir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Izmir City Hospital, Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zge","family":"\u00d6zer Kaya","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Izmir City Hospital, Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selcan","family":"Ke\u015fan","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Izmir City Hospital, Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olcun \u00dcmit","family":"\u00dcnal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Izmir City Hospital, Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"e_1_3_3_2_2","article-title":"Germline cancer susceptibility gene variants in individuals with pancreatic cancer","volume":"17","author":"Yurgelun MB","year":"2019","unstructured":"Yurgelun MB, Chittenden AB, Morales-Oyarvide V, et al. Germline cancer susceptibility gene variants in individuals with pancreatic cancer. Clin Gastroenterol Hepatol 2019; 17: 2417\u20132426.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.6228"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.3502"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/mc.20855"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2014.153"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.07.026"},{"key":"e_1_3_3_8_2","first-page":"2549","article-title":"Prevalence of germline variants in Brazilian pancreatic carcinoma patients","volume":"14","author":"da Silva C","year":"2024","unstructured":"da Silva C, Santos E, Fernandes G, et al. Prevalence of germline variants in Brazilian pancreatic carcinoma patients. Sci Rep 2024; 14: 2549.","journal-title":"Sci Rep"},{"key":"e_1_3_3_9_2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 1.2024 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf (accessed September 2025)."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy024"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.19452"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3420"},{"key":"e_1_3_3_13_2","first-page":"290","article-title":"Germline mutations of BRCA1 and BRCA2 in Japanese patients with pancreatic cancer","volume":"109","author":"Hayashi H","year":"2018","unstructured":"Hayashi H, Kato K, Takiguchi S, et al. Germline mutations of BRCA1 and BRCA2 in Japanese patients with pancreatic cancer. Cancer Sci 2018; 109: 290\u2013296.","journal-title":"Cancer Sci"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903387"},{"key":"e_1_3_3_15_2","first-page":"1","article-title":"Overall survival in patients with pancreatic cancer receiving DNA damage response\u2013targeted therapy","volume":"38","author":"Pishvaian MJ","year":"2020","unstructured":"Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic cancer receiving DNA damage response\u2013targeted therapy. J Clin Oncol 2020; 38: 1\u201310.","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000055849"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz233"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13152"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916251410475","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03008916251410475","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916251410475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:29:17Z","timestamp":1783934957000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03008916251410475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/03008916251410475"],"URL":"https:\/\/doi.org\/10.1177\/03008916251410475","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]}}}